Literature DB >> 24961930

Modulation of amyloid-β aggregation by histidine-coordinating Cobalt(III) Schiff base complexes.

Marie C Heffern1, Pauline T Velasco, Lauren M Matosziuk, Joseph L Coomes, Constantine Karras, Mark A Ratner, William L Klein, Amanda L Eckermann, Thomas J Meade.   

Abstract

Oligomers of the Aβ42 peptide are significant neurotoxins linked to Alzheimer's disease (AD). Histidine (His) residues present at the N terminus of Aβ42 are believed to influence toxicity by either serving as metal-ion binding sites (which promote oligomerization and oxidative damage) or facilitating synaptic binding. Transition metal complexes that bind to these residues and modulate Aβ toxicity have emerged as therapeutic candidates. Cobalt(III) Schiff base complexes (Co-sb) were evaluated for their ability to interact with Aβ peptides. HPLC-MS, NMR, fluorescence, and DFT studies demonstrated that Co-sb complexes could interact with the His residues in a truncated Aβ16 peptide representing the Aβ42 N terminus. Coordination of Co-sb complexes altered the structure of Aβ42 peptides and promoted the formation of large soluble oligomers. Interestingly, this structural perturbation of Aβ correlated to reduced synaptic binding to hippocampal neurons. These results demonstrate the promise of Co-sb complexes in anti-AD therapeutic approaches.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Alzheimer's disease; amyloid beta; cobalt; histidine; oligomers

Mesh:

Substances:

Year:  2014        PMID: 24961930      PMCID: PMC4166533          DOI: 10.1002/cbic.201402201

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  51 in total

Review 1.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

2.  Interference of a new cyclometallated Pt compound with Cu binding to amyloid-β peptide.

Authors:  Isabelle Sasaki; Christian Bijani; Sonia Ladeira; Valérie Bourdon; Peter Faller; Christelle Hureau
Journal:  Dalton Trans       Date:  2012-02-03       Impact factor: 4.390

3.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

Authors:  Hai-Wei Wang; Joseph F Pasternak; Helen Kuo; Helen Ristic; Mary P Lambert; Brett Chromy; Kirsten L Viola; William L Klein; W Blaine Stine; Grant A Krafft; Barbara L Trommer
Journal:  Brain Res       Date:  2002-01-11       Impact factor: 3.252

4.  Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal.

Authors:  Jason Pitt; William Roth; Pascale Lacor; Amos B Smith; Matthew Blankenship; Pauline Velasco; Fernanda De Felice; Paul Breslin; William L Klein
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-23       Impact factor: 4.219

5.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity.

Authors:  Anna K Tickler; Danielle G Smith; Giuseppe D Ciccotosto; Deborah J Tew; Cyril C Curtain; Darryl Carrington; Colin L Masters; Ashley I Bush; Robert A Cherny; Roberto Cappai; John D Wade; Kevin J Barnham
Journal:  J Biol Chem       Date:  2005-01-24       Impact factor: 5.157

7.  Abeta N-terminal-end specific antibody reduced beta-amyloid in Alzheimer-model mice.

Authors:  Yuko Horikoshi; Takashi Mori; Masahiro Maeda; Noriaki Kinoshita; Kumiko Sato; Haruyasu Yamaguchi
Journal:  Biochem Biophys Res Commun       Date:  2004-12-10       Impact factor: 3.575

Review 8.  The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease.

Authors:  Hozefa Amijee; David I C Scopes
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

10.  HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons.

Authors:  Joseph F Poduslo; Emily J Gilles; Muthu Ramakrishnan; Kyle G Howell; Thomas M Wengenack; Geoffry L Curran; Karunya K Kandimalla
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more
  7 in total

1.  Development of multifunctional heterocyclic Schiff base as a potential metal chelator: a comprehensive spectroscopic approach towards drug discovery.

Authors:  Manojkumar Jadhao; Chayan Das; Anoop Rawat; Himank Kumar; Ritika Joshi; Sudipta Maiti; Sujit Kumar Ghosh
Journal:  J Biol Inorg Chem       Date:  2016-11-07       Impact factor: 3.358

2.  Physical properties, ligand substitution reactions, and biological activity of Co(iii)-Schiff base complexes.

Authors:  A Paden King; Hendryck A Gellineau; Samantha N MacMillan; Justin J Wilson
Journal:  Dalton Trans       Date:  2019-05-07       Impact factor: 4.390

3.  Platinum(II) O,S Complexes Inhibit the Aggregation of Amyloid Model Systems.

Authors:  Daniele Florio; Anna Maria Malfitano; Sarah Di Somma; Carolin Mügge; Wolfgang Weigand; Giarita Ferraro; Ilaria Iacobucci; Maria Monti; Giancarlo Morelli; Antonello Merlino; Daniela Marasco
Journal:  Int J Mol Sci       Date:  2019-02-14       Impact factor: 5.923

4.  A catalytic antioxidant for limiting amyloid-beta peptide aggregation and reactive oxygen species generation.

Authors:  Luiza M F Gomes; Atif Mahammed; Kathleen E Prosser; Jason R Smith; Michael A Silverman; Charles J Walsby; Zeev Gross; Tim Storr
Journal:  Chem Sci       Date:  2018-12-03       Impact factor: 9.825

5.  Modification of Aβ Peptide Aggregation via Covalent Binding of a Series of Ru(III) Complexes.

Authors:  Luiza M F Gomes; Janaina C Bataglioli; Allison J Jussila; Jason R Smith; Charles J Walsby; Tim Storr
Journal:  Front Chem       Date:  2019-12-03       Impact factor: 5.221

6.  Inhibition of Beta-Amyloid Fibrillation by Luminescent Iridium(III) Complex Probes.

Authors:  Lihua Lu; Hai-Jing Zhong; Modi Wang; See-Lok Ho; Hung-Wing Li; Chung-Hang Leung; Dik-Lung Ma
Journal:  Sci Rep       Date:  2015-09-30       Impact factor: 4.379

7.  Modulation of amyloid-β aggregation by metal complexes with a dual binding mode and their delivery across the blood-brain barrier using focused ultrasound.

Authors:  Tiffany G Chan; Carmen L Ruehl; Sophie V Morse; Michelle Simon; Viktoria Rakers; Helena Watts; Francesco A Aprile; James J Choi; Ramon Vilar
Journal:  Chem Sci       Date:  2021-06-15       Impact factor: 9.825

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.